Article
TAK - 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice.
Vaccine - 26 May 2022
Tamura Kanami, Kohnoe Mai, Takashino Ayako, Kobayashi Kyousuke, Koike Satoshi, Karwal Lovkesh, Fukuda Shigeru, Vang Fue, Das Subash C, Dean Hansi J
Abstract excerpt
BACKGROUND: Enterovirus 71 (EV71) is a major cause of outbreaks of hand, foot and mouth disease, most frequently in children, and is a public health concern in the Asia-Pacific region. Takeda is developing TAK-021, an inactivated EV71 vaccine candidate based on sub-genogroup B2 strain MS87. In a phase I clinical trial, TAK-021 was safe, well tolerated, and immunogenic in healthy adults and elicited...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.